|
102 Companies |
|
136 Products |
|
136 Products |
|
123 Mechanisms of Action |
|
5 Trials |
|
1111 News |
|
| «12345678910111213...1617» |
- Trial completion: PRET: Patients Prone to Recurrence After Endovascular Treatment (clinicaltrials.gov) - Dec 7, 2015
P4, N=447, Completed, Sponsor: Centre hospitalier de l'Universit
Active, not recruiting --> Completed
- Trial primary completion date, Surgery: Fibrin Glue vs. Suture in Pterygium Surgery (clinicaltrials.gov) - Dec 5, 2015
P=N/A, N=60, Recruiting, Sponsor: Dr. Guy Ben-Simon, MD
Active, not recruiting --> Completed Trial primary completion date: Dec 2012 --> Dec 2016
- Biomarker, Trial primary completion date: Markers of Response to Intravesical Bladder Cancer Therapy (clinicaltrials.gov) - Dec 5, 2015
P=N/A, N=300, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2012 --> Dec 2016 Trial primary completion date: Aug 2016 --> Aug 2017
- azacitidine / Generic mfg.
Enrollment open: UPCI 13-165: Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS (clinicaltrials.gov) - Dec 4, 2015
P2, N=35, Recruiting, Sponsor: University of Pittsburgh
Trial primary completion date: Aug 2016 --> Aug 2017 Not yet recruiting --> Recruiting
- Enrollment closed: Monitor-AF;EPEUHM: Management of New-Onset Postoperative Atrial Fibrillation (clinicaltrials.gov) - Nov 22, 2015
P=N/A, N=50, Active, not recruiting, Sponsor: Emory University
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- tasadenoturev (DNX-2401) / DNAtrix
Enrollment closed, Oncolytic virus: D24GBM: Virus DNX2401 and Temozolomide in Recurrent Glioblastoma (clinicaltrials.gov) - Nov 15, 2015
P1, N=31, Active, not recruiting, Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- cyclophosphamide / Generic mfg., docetaxel / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores (clinicaltrials.gov) - Nov 9, 2015
P2, N=23, Terminated, Sponsor: Emory University
Recruiting --> Active, not recruiting N=65 --> 23 | Recruiting --> Terminated | Trial primary completion date: Sep 2016 --> Oct 2015; Funding withdrawn
- Trial primary completion date: FACBC for Recurrent Prostate Cancer (clinicaltrials.gov) - Oct 22, 2015
P2, N=25, Active, not recruiting, Sponsor: David M. Schuster, MD
N=65 --> 23 | Recruiting --> Terminated | Trial primary completion date: Sep 2016 --> Oct 2015; Funding withdrawn Trial primary completion date: Sep 2015 --> Dec 2015
- |||| goserelin acetate / Generic mfg.
Trial primary completion date: ELAAT: Immediate Versus Deferred Androgen Deprivation Therapy,Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy (clinicaltrials.gov) - Oct 22, 2015
P3, N=1100, Active, not recruiting, Sponsor: Ontario Clinical Oncology Group (OCOG)
Trial primary completion date: Sep 2015 --> Dec 2015 Trial primary completion date: Jun 2015 --> Dec 2015
- NN1213 / Novo Nordisk
Trial termination, Surgery: E5194: Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ (clinicaltrials.gov) - Oct 22, 2015
P2, N=711, Terminated, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Terminated; This study was terminated when the accrual goal for the low/intermediate grade stratum was reached. The high grade stratum was closed due to slow accrual.
- Enrollment change, Trial withdrawal, Trial primary completion date: Potassium Citrate Supplementation vs. Dietary Counseling (clinicaltrials.gov) - Oct 22, 2015
P2, N=0, Withdrawn, Sponsor: University of North Carolina, Chapel Hill
The high grade stratum was closed due to slow accrual. N=50 --> 0 | Enrolling by invitation --> Withdrawn | Trial primary completion date: Aug 2016 --> Aug 2015
- Enrollment closed, Trial primary completion date: MyLIFE: My Lifestyle Intervention of Food and Exercise (clinicaltrials.gov) - Oct 9, 2015
P=N/A, N=120, Active, not recruiting, Sponsor: University of Florida
N=50 --> 0 | Enrolling by invitation --> Withdrawn | Trial primary completion date: Aug 2016 --> Aug 2015 Recruiting --> Active, not recruiting | Trial primary completion date: May 2015 --> Mar 2016
- Trial completion, Trial primary completion date, HEOR: Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer (clinicaltrials.gov) - Oct 9, 2015
P=N/A, N=39, Completed, Sponsor: Ohio State University Comprehensive Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: May 2015 --> Mar 2016 Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Jan 2012
- || cyclophosphamide / Generic mfg., docetaxel / Generic mfg.
Trial primary completion date: Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores (clinicaltrials.gov) - Oct 6, 2015
P2, N=65, Recruiting, Sponsor: Emory University
Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Jan 2012 Trial primary completion date: Sep 2015 --> Sep 2016
- | Trial completion, Trial primary completion date: Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers (clinicaltrials.gov) - Oct 6, 2015
P2, N=31, Completed, Sponsor: Emory University
Trial primary completion date: Sep 2015 --> Sep 2016 Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> May 2015
- Biomarker, Enrollment change, Surgery: Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery (clinicaltrials.gov) - Sep 29, 2015
P2, N=44, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> May 2015 N=120 --> 44
- Avastin (bevacizumab) / Roche
Trial primary completion date: Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers (clinicaltrials.gov) - Sep 28, 2015
P2, N=21, Completed, Sponsor: Dana-Farber Cancer Institute
N=120 --> 44 Trial primary completion date: Feb 2012 --> Nov 2010
- | ThermoDox (lyso-thermosensitive liposomal doxorubicin) / Imunon
Enrollment closed, Trial primary completion date: DIGNITY: Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall (clinicaltrials.gov) - Sep 4, 2015
P1/2, N=20, Active, not recruiting, Sponsor: Celsion
Trial primary completion date: Feb 2012 --> Nov 2010 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Nov 2015
- Campath (alemtuzumab) / Sanofi
Trial completion, Trial primary completion date: T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies (clinicaltrials.gov) - Sep 4, 2015
P2, N=204, Completed, Sponsor: University of Chicago
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Nov 2015 Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Dec 2014
- Trial completion, Trial primary completion date, Surgery: Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC (clinicaltrials.gov) - Sep 3, 2015
P4, N=100, Completed, Sponsor: Kyoto University
Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Dec 2014 Active, not recruiting --> Completed | Trial primary completion date: Sep 2012 --> Mar 2012
- Trial completion, Trial primary completion date: RRR: Reducing Risk of Recurrence (clinicaltrials.gov) - Aug 24, 2015
P=N/A, N=150, Completed, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed | Trial primary completion date: Sep 2012 --> Mar 2012 Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Jun 2015
- |||| Trial primary completion date: Lamotrigine Phase III Study in Bipolar I Disorder (clinicaltrials.gov) - Aug 24, 2015
P3, N=250, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Jun 2015 Trial primary completion date: Mar 2016 --> Dec 2015
- || Dificid (fidaxomicin) / Merck (MSD), Astellas
Trial primary completion date: DAFNE: Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients (clinicaltrials.gov) - Aug 21, 2015
P=N/A, N=300, Recruiting, Sponsor: Astellas Pharma S.A.S.
Trial primary completion date: Mar 2016 --> Dec 2015 Trial primary completion date: Jun 2015 --> Jun 2016
- || Trial primary completion date, Metastases: Non-Interventional Study PREVENT (clinicaltrials.gov) - Aug 21, 2015
P=N/A, N=200, Recruiting, Sponsor: AstraZeneca
Trial primary completion date: Jun 2015 --> Jun 2016 Trial primary completion date: Jun 2016 --> Dec 2016
- Trial completion, Enrollment change: Longterm Outcomes of Venous Ulcers After Foam Sclerotherapy (clinicaltrials.gov) - Aug 19, 2015
P=N/A, N=67, Completed, Sponsor: Heart of England NHS Trust
Trial primary completion date: Jun 2016 --> Dec 2016 Not yet recruiting --> Completed | N=132 --> 67
- Trial primary completion date: TOSCAN: To Scan or Not to Scan: The Role of Follow-up CT Scanning for Management of Chronic Subdural Hematoma After Neurosurgical Evacuation (clinicaltrials.gov) - Aug 13, 2015
P3, N=400, Recruiting, Sponsor: University Hospital Inselspital, Berne
Not yet recruiting --> Completed | N=132 --> 67 Trial primary completion date: May 2016 --> Jun 2017
- Trial termination: SPOC: Role of a Silicone Prosthesis to Prevent Airway Obstruction Recurrence in Lung Cancers (clinicaltrials.gov) - Aug 13, 2015
P4, N=75, Terminated, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Trial primary completion date: May 2016 --> Jun 2017 Completed --> Terminated; Difficulty to include patient
- metformin / Generic mfg., sertraline / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Adding an Insulin-Sensitizing Medication to Depression Treatment for People Who Are Depressed and Overweight (clinicaltrials.gov) - Aug 12, 2015
P4, N=255, Completed, Sponsor: Washington University School of Medicine
Completed --> Terminated; Difficulty to include patient Recruiting --> Completed | N=200 --> 255 | Trial primary completion date: May 2012 --> May 2013
- | Enrollment closed: Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients (clinicaltrials.gov) - Aug 12, 2015
P3, N=164, Active, not recruiting, Sponsor: Mukoviszidose Institut gGmbH
Recruiting --> Completed | N=200 --> 255 | Trial primary completion date: May 2012 --> May 2013 Recruiting --> Active, not recruiting
- Enrollment closed: FACBC for Recurrent Prostate Cancer (clinicaltrials.gov) - Aug 11, 2015
P2, N=25, Active, not recruiting, Sponsor: David M. Schuster, MD
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Enrollment closed, Trial primary completion date, MRI: Magnetic Resonance Imaging of Mesh Position After Ventral Hernia Repair (clinicaltrials.gov) - Aug 11, 2015
P=N/A, N=15, Active, not recruiting, Sponsor: Algemeen Ziekenhuis Maria Middelares
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Sep 2016
- | Enrollment closed, Head-to-Head: OTV_PRE_01: Herbal-Based Medication vs. Placebo in Preventing Acute Otitis Media in Children at High Risk of Recurrence (clinicaltrials.gov) - Jul 25, 2015
P3, N=296, Active, not recruiting, Sponsor: University Hospital Tuebingen
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Sep 2016 Recruiting --> Active, not recruiting
- ||||||| asenapine / Generic mfg.
Trial completion: Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384) (clinicaltrials.gov) - Jul 20, 2015
P3b, N=561, Completed, Sponsor: Forest Laboratories
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Ilaris (canakinumab) / Novartis
Trial primary completion date: Canakinumab for the Prevention of Recurrences After Electrical Cardioversion: CONVERT-AF (clinicaltrials.gov) - Jul 16, 2015
P2, N=100, Recruiting, Sponsor: University Hospital, Basel, Switzerland
Active, not recruiting --> Completed Trial primary completion date: Jun 2015 --> Dec 2016
- mitoxantrone / Generic mfg.
Enrollment change, Trial withdrawal, Surgery: Mitoxantrone Following Surgery in Treating Patients With Prostate Cancer at High Risk for Recurrence (clinicaltrials.gov) - Jul 9, 2015
P2, N=0, Withdrawn, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Jun 2015 --> Dec 2016 N=60 --> 0 | Active, not recruiting --> Withdrawn
- NN1213 / Novo Nordisk
Trial completion, Enrollment change: High-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder Cancer (clinicaltrials.gov) - Jul 9, 2015
P3, N=21, Completed, Sponsor: Alliance for Clinical Trials in Oncology
N=60 --> 0 | Active, not recruiting --> Withdrawn Active, not recruiting --> Completed | N=360 --> 21
- Enrollment change: CMMV: Assessing the Rates of Major Complications in Combined Mini-incision Microscopic Varicocelectomy (clinicaltrials.gov) - Jul 6, 2015
P=N/A, N=570, Completed, Sponsor: Omid Fertility Center
Active, not recruiting --> Completed | N=360 --> 21 N=285 --> 570
- Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion, Enrollment change: Low-Dose Naltrexone (LDN) for Depression Relapse and Recurrence (clinicaltrials.gov) - Jul 2, 2015
P2, N=9, Completed, Sponsor: Massachusetts General Hospital
N=285 --> 570 Active, not recruiting --> Completed | N=36 --> 9
- ||| Trial completion, Enrollment change, Trial primary completion date: Whole-body Diffusion MRI for Staging, Response Prediction and Detecting Tumor Recurrence in Patients With Ovarian Cancer (clinicaltrials.gov) - Jul 2, 2015
P=N/A, N=350, Completed, Sponsor: Universitaire Ziekenhuizen Leuven
Active, not recruiting --> Completed | N=36 --> 9 Recruiting --> Completed | N=200 --> 350 | Trial primary completion date: Nov 2015 --> Mar 2015
- Trial completion, Trial primary completion date: Determinants of Pterygium Occurrence and Recurrence in a Rural African Population (clinicaltrials.gov) - Jun 25, 2015
P=N/A, N=355, Completed, Sponsor: Anguria, Peter, M.D.
Recruiting --> Completed | N=200 --> 350 | Trial primary completion date: Nov 2015 --> Mar 2015 Recruiting --> Completed | Trial primary completion date: Sep 2009 --> Feb 2012
- | Enrollment closed: CLOSE: Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence (clinicaltrials.gov) - Jun 24, 2015
P3, N=900, Active, not recruiting, Sponsor: Assistance Publique - H
Recruiting --> Completed | Trial primary completion date: Sep 2009 --> Feb 2012 Recruiting --> Active, not recruiting
- || Trial primary completion date: PROMIS: PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score (clinicaltrials.gov) - Jun 23, 2015
P=N/A, N=820, Recruiting, Sponsor: Agendia
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2015 --> Dec 2015
- ribavirin / Generic mfg.
Trial completion: Ribavirin Pre-treatment Followed by Combined Standard Therapy in Hepatitis C Virus (HCV) Recipients (clinicaltrials.gov) - Jun 22, 2015
P4, N=100, Completed, Sponsor: University of Roma La Sapienza
Trial primary completion date: Aug 2015 --> Dec 2015 Recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: RAPID XT: Recurrence of Arrhythmias After Pulmonary Veins Isolation Detected by ICM (clinicaltrials.gov) - Jun 20, 2015
P4, N=47, Completed, Sponsor: Dr Ange FERRACCI
Recruiting --> Completed Recruiting --> Completed | N=60 --> 47 | Trial primary completion date: Jan 2011 --> Dec 2012
- |||||| Enrollment open: Reducing Residual Depressive Symptoms With Web-based Mindful Mood Balance (clinicaltrials.gov) - Jun 18, 2015
P3, N=460, Recruiting, Sponsor: University of Toronto
Recruiting --> Completed | N=60 --> 47 | Trial primary completion date: Jan 2011 --> Dec 2012 Not yet recruiting --> Recruiting
- ||| Ruoxinlin (toludesvenlafaxine extended release) / Luye Group
Trial completion, Enrollment change: Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005 (clinicaltrials.gov) - Jun 18, 2015
P1, N=58, Completed, Sponsor: Luye Pharma Group Ltd.
Not yet recruiting --> Recruiting Recruiting --> Completed | N=48 --> 58
- Trial completion: ENERGY: Reducing Breast Cancer Recurrence With Weight Loss (clinicaltrials.gov) - Jun 18, 2015
P=N/A, N=692, Completed, Sponsor: University of California, San Diego
Recruiting --> Completed | N=48 --> 58 Active, not recruiting --> Completed
- Trial primary completion date: Mucosal Versus Fecal Microbiota in FMT (clinicaltrials.gov) - Jun 16, 2015
P=N/A, N=20, Recruiting, Sponsor: Emory University
Active, not recruiting --> Completed Trial primary completion date: Jul 2015 --> Jul 2016
- || Trial primary completion date: Recurrence Following Nonoperative Management of 1st Episode of Hinchey II Diverticulitis (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=75, Recruiting, Sponsor: Stony Brook University
Trial primary completion date: Jul 2015 --> Jul 2016 Trial primary completion date: Dec 2014 --> Dec 2015
- tasadenoturev (DNX-2401) / DNAtrix
Trial primary completion date, Oncolytic virus: D24GBM: Virus DNX2401 and Temozolomide in Recurrent Glioblastoma (clinicaltrials.gov) - Jun 11, 2015
P1, N=31, Recruiting, Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Mar 2015 --> Dec 2015